Comparison of Patient Study Group Characteristics
Parameter . | HHT-IFN-α Group (n = 90) . | IFN-α Historical Controls (n = 274) . |
---|---|---|
Median age (yrs) (range) | 45 (20-75) | 42 (14-76) |
Median WBC count ×109/L (range) | 82.5 (10-349) | 115 (2-632) |
Median hemoglobin level (g/dL) (range) | 12.9 (8.5-16.9) | 12.0 (5.0-16.8) |
Median platelet count ×109/L (range) | 418 (115-1,172) | 409 (125-2,343) |
Median time from diagnosis in months (range) | 1.5 (1-11) | 2.5 (0-12) |
Symptoms at diagnosis (%) | 62 | 64 |
Palpable splenomegaly (%) | 37 | 53 |
Clonal evolution (%) | 11 | 2 |
Prognostic group (%) | ||
Good | 33 | 42 |
Intermediate | 40 | 31 |
Poor | 9 | 14 |
Not applicable | 18 | 13 |
Parameter . | HHT-IFN-α Group (n = 90) . | IFN-α Historical Controls (n = 274) . |
---|---|---|
Median age (yrs) (range) | 45 (20-75) | 42 (14-76) |
Median WBC count ×109/L (range) | 82.5 (10-349) | 115 (2-632) |
Median hemoglobin level (g/dL) (range) | 12.9 (8.5-16.9) | 12.0 (5.0-16.8) |
Median platelet count ×109/L (range) | 418 (115-1,172) | 409 (125-2,343) |
Median time from diagnosis in months (range) | 1.5 (1-11) | 2.5 (0-12) |
Symptoms at diagnosis (%) | 62 | 64 |
Palpable splenomegaly (%) | 37 | 53 |
Clonal evolution (%) | 11 | 2 |
Prognostic group (%) | ||
Good | 33 | 42 |
Intermediate | 40 | 31 |
Poor | 9 | 14 |
Not applicable | 18 | 13 |